anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Previous studies have reported various anatomical differences in the cerebral artery between healthy subjects and patients with posterior circulation cerebral infarction. In particular, basilar artery angulation has been associated with posterior circulation cerebral infarction. We compared anatomical variations and the degree of anterior and lateral vertebrobasilar artery angulation and deviation to compare the incidence of cerebral infarction of healthy subjects and patients with posterior circulation cerebral infarction. We compared basilar artery anatomy using brain magnetic resonance angiography in 97 patients who underwent brain magnetic resonance angiography during health checkups at our hospital and in 92 patients diagnosed with posterior circulation cerebral infarction between 2012 and 2022. Anatomical variations, including fetal-type posterior cerebral artery, hypoplastic P1 segment, vertebrobasilar dolichoectasia, and dominant vertebral artery, as well as the degree of anterior and lateral deviation and angulation, were evaluated. Correlations between these variations and the occurrence of cerebral infarction were analyzed. The prevalence of hypoplastic P1 was significantly differences in patients with posterior circulation cerebral infarction (odds ratio: 5.655). Furthermore, patients with posterior circulation cerebral infarction exhibited more acute anterior and lateral angulation, as well as lateral deviation. Hypoplastic P1 and more acute anterior or lateral angulation of the vertebrobasilar artery are associated with increased frequency of cerebral infarction.
PROBLEM TO BE SOLVED: To obtain an anti-pruritus agent having excellent itching-relieving activities against an itching based on an allergy and infectious disease, especially urtiated example of antihistamine by using a macrolide antibiotic as an active ingredient. SOLUTION: This anti-pruritus agent contains a macrolide antibiotic (e.g. roxithromycin, clarithromycin, erythromycin and oleandomycin) as an active ingredient. The administration form of the anti-pruritus agent is, for example, an oral preparation such as a powder and a fine subtilae, a preparation for external use such as an ointment and a plaster, a suppository, a preparation for injection, etc. The oral preparation can be prepared by adding an excipient (e.g. a lactose and a cone starch), and optionally an antioxidant, a binder (e.g. a polyvinyl alcohol and a polyvinyl ether), a disintegrator (e.g. a starch, an agar and a gelatin powder), etc., thereto. The clinical daily dose of the macrolide antibiotic, e.g. that of the roxithromycin is preferably 100-500 mg.
1,183,969. o-Anilino-phenylacetic acids. J. R. GEIGY A.G. 6 Oct., 1967 [7 Oct., 1966], No. 45727/67. Heading C2C. Novel o-anilino-phenylacetic acids of the general formula wherein R 1  is a low alkyl or alkoxy group, a fluorine, chlorine or bromine atom or the trifiuoromethyl group; R 2  is hydrogen or is defined as R 1 ; R 3  is hydrogen, a low alkyl or alkoxy group or a fluorine, chlorine or bromine atom; R 4  is hydrogen, a low alkyl or alkoxy group, a fluorine, chlorine or bromine atom or the trifluoromethyl group; R 5  is a low alkyl group; and R 6  and R 7  are each hydrogen, a low alkyl group or a benzyl group; and salts thereof with inorganic and organic bases are prepared by hydrolysis of an o-anilino-phenylacetic acid ester or an o-anilino-phenylacetonitrile of the respective formulµ wherein R 8  is a hydrocarbon radical having at most 10 carbon atoms, or, when R 8  is the benzyl radical, by hydrogenolysis of an o-anilinophenylacetic acid ester of the second general formula above with catalytically activated hydrogen; followed optionally by conversion of the product into a salt thereof with an inorganic or organic base. o-Anilino-phenylacetonitriles of the third general formula above wherein R 6  and R 7  are hydrogen atoms are prepared by alkylation of an appropriately substituted N - phenylanthranilic acid alkyl ester, reduction of the resulting substituted N-alkyl-N-phenyl-anthranilic acid alkyl ester, reaction of the obtained substituted o - anilino - benzyl alcohol with phosphorus tribromide and treatment of the produced substituted o-anilino-benzyl bromide with potassium cyanide. o - Anilino - phenylacetic acid esters of the second general formula above are prepared by reaction of an o-anilino-phenylacetonitrile of the third general formula above with a solution of hydrogen chloride and an alcohol, followed by treatment with water. Pharmaceutical compositions having antiphlogistic, analgesic and antipyretic activity comprise an o-anilino-phenylacetic acid of the first general formula above or a salt thereof with an inorganic or organic base in combination with an inert carrier.
The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
Frailty, a multidimensional indicator of suboptimal aging, reflects cumulative declines across multiple physiological systems. Although age-related changes have been reported in gut microbiota, their role in healthy aging remains unclear. In this study, we calculated frailty index (FI) from 33 health-related items to reflect the overall health status of 1,821 older adults (62-96 years, 55% female) and conducted multi-omics analysis using gut metagenomic sequencing data and plasma metabolomic data. We identified 18 microbial species and 17 metabolites shifted along with frailty severity, with stronger links observed in females. The associations of nine species, including various Clostridium species and Faecalibacterium prausnitzii, with FI were reproducible in two external populations. Plasma glycerol levels, white blood cell count and kidney function partially mediated these associations. A composite microbial score derived from FI significantly predicted 2-year mortality (adjusted hazard ratio across extreme quartiles, 2.86; 95% confidence interval, 1.38-5.93), highlighting the potential of microbiota-based strategies for risk stratification in older adults.
PURPOSE: To provide a mixing device for mixing a gaseous substance with a gas stream. CONSTITUTION: In this device of the present invention, a gaseous substance is fed to a mixing chamber 1 by means of a carrier gas 23 via a line 10. The line 10 has at least one capillary tube 19 arranged in an advancing device 9 with two defined positions. In a first position, the capillary tube 19 extends through an opening 6 into the mixing chamber 1. In a second position, the capillary tube 19 opens outside of the mixing chamber 1 in a suction removal space 25 surrounding the mixing chamber 1. Preferably the carrier gas 23 is flowing continuously. A suction removal means 26 provided to remove the carrier gas 23 together with the gaseous substance from the capillary tube 19, when the capillary tube 19 opens in the suction removal space 25.
Information available in the published literature suggests that the primary enzyme responsible for the metabolism of albuterol enantiomers in humans is SULT1A3 (sulfotransferase). When racemic albuterol was administered either intravenously or via inhalation after oral charcoal administration, there was a 3- to 4-fold difference in the area under the concentration-time curves between the (R)- and (S)-albuterol enantiomers, with (S)-albuterol concentrations being consistently higher. However, without charcoal pretreatment, after either oral or inhalation administration the differences were 8- to 24-fold, suggesting that (R)-albuterol is preferentially metabolized in the gastrointestinal tract, presumably by SULT1A3.

The primary route of elimination of albuterol enantiomers is through renal excretion (80% to 100%) of either the parent compound or the primary metabolite. Less than 20% of the drug is detected in the feces. Following intravenous administration of racemic albuterol, between 25% and 46% of the (R)-albuterol fraction of the dose was excreted as unchanged (R)-albuterol in the urine.
PROBLEM TO BE SOLVED: To obtain a medicine which dissolves even at neutral to alkaline conditions and is usable at a weak alkaline condition similar to the living body, in local anesthetics. SOLUTION: This local anesthetic aqueous solution contains a local anesthetic clathrated with a cyclodextrin or its derivative in an amount of 0.02 wt.% or more at the concentration of the local anesthetic itself and the pH is 6.5-8.5. Further, salicylic acid or its salt is blended with this local anesthetic aqueous solution. The method of improving the solubility of the local anesthetic in water at pH 6.5-8.5 is carried out by clathrating the local anesthetic with the cyclodextrin or its derivative. Since this local anesthetic aqueous solution shows pH 6.5-8.5 and can be used at the pH similar to that of the living body, it is effective even in the case that the pH of the living body tissue is inclined toward the acidic side. Further, the pain due to local acidoses which are observed in infusion parts of usual local anesthetics dissolved into acidic solutions can be decreased.
This invention provides an article of manufacture and method for controlling the application of a coupling agent, such as a silicone oil or mineral oil, on a surface of a tissue prior to contacting the tissue with an apparatus for non-invasive optical measurement of the concentration of an analyte. Such an apparatus is shown in WO 99/59464. The article ensures that a specific quantity of the coupling agent is deposited in a uniform layer over the entire target area of the tissue, thereby enhancing both the optical signal and the repeatability of thermal and optical coupling with the components of the apparatus. The coupling agent can comprise any of the coupling agents described in U.S. Pat. No. 6,241,663 that have desirable coupling properties for this application. In one embodiment, the article comprises (a) a backing and (b) a layer of coupling agent on at least one major surface of the backing. In this embodiment, the material of the backing must not absorb an excessive amount of the coupling agent. In an alternative embodiment, the article can comprises (a) a backing, (b) a layer of fibrous or non-fibrous material overlying the backing, and (c) a layer of coupling agent on the major surface of the layer of fibrous or non-fibrous material not in contact with the backing. In the alternative embodiment, the layer of layer of fibrous or non-fibrous material prevents the coupling agent from being absorbed by the backing.
Provided are nucleic acids encoding chimeric cytokine receptors (CCRs) capable of signaling in the absence of their cognate cytokines. In some embodiments, provided are one or more nucleic acids encoding a first subunit of a chimeric cytokine receptor and a second subunit of the chimeric cytokine receptor. The first subunit comprises a first heterologous dimerization domain and a first cytokine receptor intracellular signaling domain (ICD). The second subunit comprises a second heterologous dimerization domain cognate for the first heterologous dimerization domain, and a second cytokine receptor ICD. The CCRs find use in a variety of contexts, including but not limited to, increasing the persistence of therapeutic cells. Accordingly, also provided are methods of administering a cell-based therapy, the methods comprising administering therapeutic cells (e.g., CAR-T cells, etc.) expressing the CCRs to a subject in need thereof.
A method for communicating between a first Fibre Channel (FC) enabled device and a second FC enabled device, where the communication occurs across a fabric that operates in accordance with a first protocol different from a FC protocol of the first and second FC enabled devices. The method includes receiving, from the first FC enabled device, at a first gateway receiver a sequence of bytes including at least one control character in accordance with the FC protocol. The method then includes replacing the at least one control character with at least one data character. The method also includes generating an encapsulation header and an encapsulation footer for encapsulating the sequence of bytes in which at least one control character was replaced with at least one data character. The method then includes setting a control character indicator in the encapsulation header if a first byte in the sequence of bytes received at the gateway receiver is a control character. The method includes setting an end of frame indicator in the encapsulation footer if a last byte in the sequence of bytes received at the first gateway receiver is an end of frame control character.
Patients receive metformin hydrochloride PO QD or BID for 24 months. Patients will continue metformin 850 mg PO BID for months 13-24. Patients will undergo RPFNA at 24 months. Follow up visits will be performed at 36 and 48 months after the start of treatment.
Circular RNAs are a class of covalently closed single-stranded loop RNAs that have been implicated to play a functional role in almost all types of cancers. Previous studies have revealed that circMYBL2 acts as a tumor-promoting circular RNA. In this study, we found that circMYBL2 in colorectal cancer encodes a 185-amino acid protein, p185. Functionally, circMYBL2-encoded p185 suppressed the growth and aggressiveness of colorectal cancer cells in vitro and in vivo. Mechanistically, p185 counteracted ubiquitin C-terminal hydrolase L3 (UCHL3)-mediated deubiquitination of phosphoglycerate dehydrogenase (PHGDH) by competitively binding to the C1 domain of UCHL3, resulting in PHGDH degradation and a subsequent reduction in serine and glycine biosynthesis. These data revealed that the circMYBL2-encoded p185 isoform serves as a tumor suppressor to inhibit the progression of colorectal cancer by reducing serine biosynthesis. Significance: A p185 protein encoded by circMYBL2 functions as a tumor suppressor that inhibits the progression of colorectal cancer by increasing the degradation of PHGDH to reduce serine biosynthesis.
An aneurysmal bone cyst (ABC) is a benign bone neoplasm that typically occurs during the first and second decades of life. ABC usually presents as a rapidly growing intramedullary expansile mass with multiple blood-filled cysts in the metaphysis of the long tubular bones. Here, we report a case of a periosteal solid ABC that was initially diagnosed as a high-grade surface osteosarcoma. A 10-year-old male was referred to our hospital for swelling and tenderness of the left upper arm. Radiography revealed periosteal mass without fluid-fluid levels. On performing open biopsy, the tumor showed hypercellular proliferation of uniform spindle to epithelioid cells with brisk mitotic activity (up to 12/2 mm2) and lace-like osteoid formation, which was diagnosed as a high-grade surface osteosarcoma. After one course of chemotherapy using adriamycin and cisplatin, peripheral sclerosis was conspicuous, which led to pathological review and revision of diagnosis as "possibly osteoblastoma." The patient was disease-free for 4 years after marginal resection and curettage. Retrospective nanopore DNA sequencing unexpectedly detected a PAFAH1B1::USP6 rearrangement. The fusion gene was further validated using reverse transcription-polymerase chain reaction and the diagnosis was revised to ABC. Chromothripsis involving chromosome 17 has also been identified. Methylation analysis classified the present tumor as an ABC or non-ossifying fibroma using t-distributed stochastic neighbor embedding and unsupervised hierarchical clustering. This case report highlights the utility of nanopore DNA sequencing for soft tissue and bone tumor diagnosis.
Treatment will follow a 28-day cycle. Participants will take one placebo capsule orally on days 1, 8, and 15 of each 28-day cycle, followed by one treatment-free, in sequence, for the duration of the trial.
Patients were randomized into three groups using a computer-based program (ratio 1:1:1), and the assigned surgical technique was disclosed just before surgery. At the time of surgery, the sealed opaque envelope, numbered consecutively and containing the description of the suturation technique, was given to the operator. Suturing techniques varied between groups: double layer continuous, non-locking suturing with endometrial inclusion, second layer imbricating the first layer (Group 1), double layer, continuous, non-locking suturing without endometrial inclusion second layer imbricating the first layer (Group 2) and double layer continuous with the first layer unlocked, including the endometrium and the deep part of the myometrium, and the second layer continuous unlocked including the remaining part of the myometrium (Group 3) (Figure 2). Size 1 polyglycolic acid 910 (Vicryl ® Ethicon Inc. Somerville, NJ) was used as suture material in all groups.

Patients were re-evaluated at the sixth month as uterine scar healing is reported to be completed within six months and preoperative assessments were repeated. Transvaginal ultrasonography was performed by an investigator blinded to suturing techniques. Measurements included RMT, and CSD assessment (as the primary outcomes) (including the depth and width of the CSD), as well as other routine ultrasonographic evaluations. Transvaginal sonography was performed by the same investigator with a Toshiba Applio 500 device using a PMW-621VT 6 Mhz R13 probe. CSD was considered when myometrial continuity in the previous caesarean incision site was lost, and an anechoic defective area towards the myometrium was noted. In patients who did not develop CSD, the incision line was measured anteriorly, and the symmetrical posterior uterine wall thickness was measured. In patients with CSD, the myometrium tissue above the anechoic defective area was evaluated as residual myometrial thickness. The CSD sac's depth and its base's width were measured. The full-thickness myometrium adjacent to the defect area was measured, and recovery rates were calculated by taking the percentage of the residual myometrial thickness over the defect to the full-thickness myometrium.
The HIV epidemic is a major global health challenge, causing tremendous human suffering and economic loss throughout the world. The need for a safe, effective, and affordable HIV preventive vaccine is critical. This 2-part study will determine the safety and immunogenicity of the experimental HIV vaccine HIV-1 gag DNA with or without IL-15 adjuvant, boosted with either the HIV-1 gag DNA and IL-15 adjuvant vaccine or the HIV-1 gag DNA and IL-12 adjuvant vaccine.

There are two parts to this study. Part A will last 12 months. In Part A, 48 participants will be randomly assigned to 1 of 4 groups in sequential order (dose escalation). All participants will receive 3 vaccinations. Group 1 will receive 3 vaccinations of the HIV-1 gag DNA vaccine or placebo. Group 2 will receive 3 vaccinations of either the HIV-1 gag DNA vaccine with a low dose of IL-15 adjuvant or a placebo. Group 3 will receive 3 vaccinations of either the HIV-1 gag vaccine with a medium dose of IL-15 adjuvant or a placebo. Group 4 will receive 3 vaccinations of either the HIV-1 gag vaccine with a high dose of IL-15 adjuvant or a placebo. Vaccinations will be given at Months 0, 1, and 3. There will be 11 study visits in Part A. A physical exam, pregnancy prevention counseling, medication history, and adverse event reporting will occur at most visits. Urine and blood collection will occur at some visits. Participants will also be asked to complete questionnaires at certain visits.

Part B will last 15 months. In Part B, 72 participants will be randomly assigned to 1 of 2 groups. All Part B participants will receive 5 vaccinations. Group 5 will receive 5 vaccinations of either the HIV-1 gag vaccine plus IL-15 DNA or placebo; the vaccinations will occur at Months 0, 1, 3, 6, and 9. Group 7 will receive 3 vaccinations of the HIV-1 gag vaccine with a high dose of IL-15 adjuvant (maximum tolerated dose from Part A) followed by 2 vaccinations of the gag DNA vaccine with IL-12 DNA adjuvant. Some participants will receive placebo instead of this vaccine regimen. For Group 7, the HIV-1 gag vaccine with IL-15 adjuvant vaccinations will be given at Months 0, 1, and 3, and booster vaccinations will be given at Months 6 and 9. There will be 13 study visits in Part B. A physical exam, pregnancy prevention counseling, medication history, and adverse event reporting will occur at most visits. Urine and blood collection will occur at some visits. Participants will also be asked to complete questionnaires at certain visits.
In this study 140 patients who have had a recent hospitalization for an acute coronary syndrome and who have major depression will all receive 12 weeks of treatment with the antidepressant citalopram and regular clinical management visits from a mental health professional. The objective is to examine the characteristics of depressed cardiac patients who do and do not show an improvement in depression with citalopram treatment. There is evidence that the causes of depression may be different in some people with cardiac disease than in individuals who do not have heart problems, and these differences may be at least partially involved in determining response to antidepressant treatment. Inflammation, one of the body's responses to the development of atherosclerosis (hardening of the arteries and blockages in the heart) may be particularly important in producing depression in cardiac patients. There may also be changes in the body's metabolism of tryptophan, a protein that is involved in making serotonin, and levels of serotonin are often low in depression. Other factors thought to influence the development of depression include childhood experiences and personality factors. Heredity and family history also seem to play a role in some people with depression and heart disease. Finally, some patients experience sleep apnea, interruptions in breathing while they are asleep, that can contribute to both cardiac disease and depression.
The pathophysiology of affective disorders-particularly circuit-level mechanisms underlying bidirectional, periodic affective state transitions-remains poorly understood. In patients, disruptions of sleep and circadian rhythm can trigger transitions to manic episodes, whereas depressive states are reversed. Here, we introduce a hybrid automated sleep deprivation platform to induce transitions of affective states in mice. Acute sleep loss causes mixed behavioral states, featuring hyperactivity, elevated social and sexual behaviors, and diminished depressive-like behaviors, where transitions depend on dopamine (DA). Using DA sensor photometry and projection-targeted chemogenetics, we reveal that elevated DA release in specific brain regions mediates distinct behavioral changes in affective state transitions. Acute sleep loss induces DA-dependent enhancement in dendritic spine density and uncaging-evoked dendritic spinogenesis in the medial prefrontal cortex, whereas optically mediated disassembly of enhanced plasticity reverses the antidepressant effects of sleep deprivation on learned helplessness. These findings demonstrate that brain-wide dopaminergic pathways control sleep-loss-induced polymodal affective state transitions.